The burgeoning popularity of retatrutide, initially for diabetes , is creating significant interest within the UK , prompting a notable shift in peptide trends. Availability these treatments remains a complex challenge , with NHS provision currently limited and specialist practices offering treatment at a higher cost . Questions are being raised re